

ASH MEETING ISSUE:

IPHA/ASH Meeting

NIH Initiatives

IPHA/ASPN Meeting

Alan B. Gruskin, MD

FDA Report

Normal ABP Values

Committee Reports

Financial
Education
Research

New Committees

Communication
Clinical Trials Committee

Web Site

Executive Committee

Bruce Alpert
Bonita Falkner
Gregory Harshfield
Empar Lurbe
Bruce Morgenstern
Elke Wuehl

For submissions to the newsletter
please contact:

Jennifer Turner at:
713.500.5113

Jennifer.LTurner@uth.tmc.edu

PEDHTN is administrated
by:

Ron Portman Mail to:
Ronald..Portman@uth.tmc.edu
& by Andrew Aronson Mail
to: drandrewj@triton.net

IPHA ACTIVITIES AT AMERICAN SOCIETY OF HYPERTENSION MEETING MAY 2003

Friday, May 16th, 2003

3:30-5:00 PM IPHA Executive Committee meeting,
Duffy Room

7:30 PM Dinner for Executive Committee with invited
speakers (Empar Lurbe, Valentina Kon, Elke
Wuehl). Place to be determined.

Saturday, May 17, 2003

7-8:30 AM Pediatric hypertension poster session,
with 'guided tour' of the pediatric hypertension posters
by Bruce Alpert, MD.

**“Role of Blood Pressure in the Progression of
Childhood Renal Disease: Implications for
Therapy.”**

Moderators: Bonita Falkner, MD and Julie Ingelfinger,
MD.

**Cardiovascular Risk Factors and the Kidney in
Children with Chronic Kidney Disease**

Speaker: Valentina Kon MD, Vanderbilt University

**Predictors of Progression in Hypertensive Renal
Diseases in Children**

Speaker: Empar Lurbe MD, University of Valencia,
Spain

**Renoprotection, Cardioprotection and Children
with Renal Disease: Evidence.**

Speaker: Elke Wuehl MD, Heidelberg, Germany

Original Communications

12:30-2:30 Membership Luncheon/business meeting
Duffy Room

NIH INITIATIVES

Dr. Bruce Alpert has taken a leadership role in meeting with Paul Velletri, Ph.D., leader of the Hypertension Scientific Research Group at the NIH. Dr. Velletri reviewed a document submitted by IPHA with suggestion for future research in pediatric hypertension. Several mechanisms were suggested which might be developed to enhance discussions. Dr Velletri suggested that his working group has a great deal of interest in genetic issues outlined in the submitted document. Dr. Velletri also suggested that a member of his staff, Gail Pearson, M.D., could serve as a contact-person for discussion of other basic issues in BP measurement which require further prospective data collection.

NHLBI UPDATES

The National Heart, Lung, and Blood Institute, under the direction of Dr. Claude Lenfant, Plans to support an update of the guidelines on childhood hypertension. **Dr. Bonita Falkner** will be working with Dr. Ed Roccella, Director of the National High Blood Pressure Education Program, in the organization and planning of this project. Six focus areas have been identified for review and update by national experts, at an NHLBI sponsored Workshop.

The six areas are:

1) Blood Pressure Percentiles, considering new NHANES data, 2) Target organ damage in children, 3) Instruments for measuring blood pressure in children, 4) Antihypertensive drug use in children, 5) Non-drug therapy and lifestyle issues in children, 6) Sleep and sleep deprivation issues.

The overall goal of this project is the development of user friendly statements for use by primary care clinician. The NIH sponsored conference is expected to be in December 2003 in Washington, DC.

PEDIATRIC ACADEMIC SOCIETIES MEETING MAY 2003

A session jointly sponsored by the American Society of Pediatric Nephrology and IPHA took place at the Pediatric Academic Society meeting in Seattle two weeks ago.

Drs. Sorof and Flynn will moderated an excellent session on Hypertension-Related Target Organ Damage in Children. Presentations will include:

**Detection of TOD in children through
echocardiographic, renal, and retinal manifestations.**

Stephen Daniels, MD, Pediatric Cardiology, Children's Hospital and Medical Center Cincinnati, Ohio.

**What is the BP threshold for the development of TOD
in children?**

Jonathan Sorof MD, University of Texas, Houston, Texas

Hypertension-induced vascular injury

Sam Gidding, MD, MCP/Hahneman, Philadelphia, PA.

**Pathophysiology of microalbuminuria in hypertension
and reversibility with treatment.**

George Bakris, MD, Presbyterian Medical Center,
Chicago, Illinois

In addition, there were many excellent presentations by IPHA members.

ALAN B. GRUSKIN, MD PRESENTED IPHA'S FIRST CAREER ACHIEVEMENT AWARD

It is with great sadness that we acknowledge the loss of a great contributor to the field of pediatric hypertension, Alan B. Gruskin last month. We are pleased, however; that we were able to recognize his great contributions. The crystal award in the shape of a flame was inscribed, "To Alan B. Grushkin for illuminating our path in the field of pediatric hypertension" Alan will be sorely missed but he lives on though through his important contributions.

IPHA MEETS WITH FDA

On March 16 and 17th, IPHA and other representatives of the pediatric community met with Douglas Throckmorton, MD and other members of the FDA Cardio-Renal Section. In attendance were Russell Chesney, Julie Ingelfinger, Thomas Wells, Joseph Flynn, Jon Sorof, Marva Moxey-Mims, Steve Daniels and Ron Portman. Presentations included an overview of Pediatric Hypertension by Ron Portman, Pharmacology of Antihypertensive in Children by Tom Wells, Pharmacogenetics by Julie Ingelfinger and End Organ Damage Studies by Jon Sorof. There was a very cooperative and constructive spirit to the meeting. We discussed the possibility of adding more scientific questions to these studies perhaps in cooperation with the NIH, the need to make pediatric dosage forms commercially available and seek a pediatric indication for all of these drugs and issues related to the newest age group to be included in these trials, age 1-6 years. We feel that the groundwork for future communication and cooperation has been laid.

IPHA ABPM NORMATIVE DATA PROJECT:

Empar Lurbe, Joseph Flynn, Greg Harshfield

Committee Reports

Financial: Portman

Education: Flynn/Falkner

Research: Sorof

New Proposed Committees

Communication

Clinical Trials Committee

IPHA WEBSITE UPDATES

It is a great pleasure to announce that the IPHA website server has been relocated to a more accessible internet provider. Numerous users reported consistent connectivity problems and network downtime due to virus attack or security protocol implementation.

The new location is a direct connection to the internet and has been confirmed as accessible by all users to date. The name, www.pediatrichypertension.org, has not changed. All previous content is still available and new content will be added on a weekly basis for the near term. Each Tuesday afternoon is dedicated to website advancement.

Previous content included:

- Membership contact information
- Archive of past IPHA publications
- IPHA events library
- List of current IPHA projects
- Listserver instructions
- Pediatric limits online calculator
- Data sharing protocol description for submitting to the IPHA database

- Page of useful internet links
- Recognition of donations to IPHA

As in the past the private section of the IPHA website is accessible using the following logon:

- ID: vascular
- Password: angiotensin

Anyone having trouble accessing the website or wishing to submit suggestions / material should email the webmaster or contact Tim Poffenbarger at 713-500-5720.

NEW BUSINESS

New meetings:

Possible meeting at IPNA

Combined meeting with European Group

Possible IPHA Symposium